Home » Stocks » AMPH

Amphastar Pharmaceuticals, Inc. (AMPH)

Stock Price: $17.79 USD 0.42 (2.42%)
Updated Mar 3, 2021 3:59 PM EST - Market closed
After-hours: $17.78 -0.01 (-0.06%) Mar 3, 4:01 PM
Market Cap 824.19M
Revenue (ttm) 337.31M
Net Income (ttm) 6.65M
Shares Out 47.50M
EPS (ttm) 0.14
PE Ratio 131.78
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $17.79
Previous Close $17.37
Change ($) 0.42
Change (%) 2.42%
Day's Open 17.48
Day's Range 17.20 - 17.86
Day's Volume 212,036
52-Week Range 12.33 - 22.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

RANCHO CUCAMONGA, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications ...

Seeking Alpha - 1 month ago

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AQUA, BBDC, BHVN, CFX, CRHM, GBT, HASI, HMHC, LXRX, MNKD, NKTR, NNOX, OBSV, PSNL, PTY, ROAD, SGRY, SP, TAK, UTF, XRM
GlobeNewsWire - 2 months ago

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbrev...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.

Investopedia - 2 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMRX, BIIB, HZNP, PAHC, SUPN
GuruFocus - 3 months ago

Growth-focused investors may want to consider the following small-cap stocks as they represent companies whose trailing 12-month pro forma earnings per share improved significantly on a year-o...

Other stocks mentioned: GLDD, PBH
Seeking Alpha - 3 months ago

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

Amphastar Pharmaceuticals' (AMPH) Management on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 3 months ago

Amphastar (AMPH) delivered earnings and revenue surprises of 15.39% and -8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020

Zacks Investment Research - 4 months ago

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor in Amphastar.

Zacks Investment Research - 4 months ago

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

GlobeNewsWire - 4 months ago

RANCHO CUCAMONGA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s A...

GlobeNewsWire - 6 months ago

RANCHO CUCAMONGA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate C...

Seeking Alpha - 6 months ago

Amphastar Pharmaceuticals' (AMPH) Management on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

On Thursday, August 06, Amphastar Pharmaceuticals (NASDAQ: AMPH) will release its latest earnings report.

GlobeNewsWire - 7 months ago

RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ende...

GlobeNewsWire - 8 months ago

RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Co...

GlobeNewsWire - 8 months ago

RANCHO CUCAMONGA, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Co...

Investopedia - 8 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: CRON, NLTX
GlobeNewsWire - 8 months ago

RANCHO CUCAMONGA, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Amphastar® Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”)...

GlobeNewsWire - 9 months ago

RANCHO CUCAMONGA, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO and Dan Dischner, Vice President of Corporate...

Seeking Alpha - 9 months ago

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GlobeNewsWire - 10 months ago

RANCHO CUCAMONGA, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”),  today announces that the U.S. Food and Drug Administration (“FDA”...

GlobeNewsWire - 10 months ago

RANCHO CUCAMONGA, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceuti...

Seeking Alpha - 11 months ago

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

RANCHO CUCAMONGA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval...

GlobeNewsWire - 1 year ago

RANCHO CUCAMONGA, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that on January 24, 2020, the U.S. Food and Drug Administration (“FDA”) ...

Seeking Alpha - 1 year ago

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

RANCHO CUCAMONGA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be prese...

Seeking Alpha - 1 year ago

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Amphastar (AMPH) delivered earnings and revenue surprises of 166.67% and 4.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

InvestorPlace - 1 year ago

TerraForm Power, Zillow Group and Boston Scientific are just some of the top stocks to buy as May turns into June. The post 7 Stocks to Buy for June appeared first on InvestorPlace.

Other stocks mentioned: BSX, KFRC, LSI, TERP, VLGEA, Z, ZG
Zacks Investment Research - 1 year ago

Amphastar (AMPH) delivered earnings and revenue surprises of 233.33% and 6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

MNK vs. AMPH: Which Stock Is the Better Value Option?

Other stocks mentioned: MNK
Zacks Investment Research - 1 year ago

MNK vs. AMPH: Which Stock Is the Better Value Option?

Other stocks mentioned: MNK
Zacks Investment Research - 1 year ago

MNK vs. AMPH: Which Stock Is the Better Value Option?

Other stocks mentioned: MNK
Investors Business Daily - 1 year ago

Amphastar Pharmaceuticals plunged Wednesday despite its better-than-expected fourth-quarter earnings on a lack of key drug approvals expected in 2019.

Benzinga - 1 year ago

On Tuesday, March 12, Amphastar Pharmaceutical will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

About AMPH

Amphastar Pharmaceuticals, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermit... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 25, 2014
CEO
Jack Zhang
Employees
2,027
Stock Exchange
NASDAQ
Ticker Symbol
AMPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is 21.80, which is an increase of 22.54% from the latest price.

Price Target
$21.80
(22.54% upside)
Analyst Consensus: Buy